Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines

• Autors principals: Anthony M. Marchese (Autor), Raj Kalkeri (Autor), Muruga Vadivale (Autor), Nungruthai Suntronwong (Autor), Seth Toback (Autor), Yong Poovorawan (Autor)
• Format: Llibre
• Publicat: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Introduction Approximately half of the 13.4 billion COVID-19 vaccine doses administered globally were inactivated or viral vector platforms. The harmonization and optimization of vaccine regimens has become a key focus of policymakers and health-care providers and presents an opportunity to reassess...